Protagonist Therapeutics

US · PTGX #1570 by market cap Listed 2016

140.92 +2.23 +1.61%

Live - 5344 symbols - heartbeat 301s ago · 2026-10-08 04:39

Pre-market 141.00 +0.06%

After-hours 140.92 0.00%

Market cap: 9.12B
P/E (TTM): 136.82
P/B: 10.84
EPS: -2.05
Div yield: 0.00%
52W pos: 77%

Reader sentiment Are you bullish or bearish on PTGX?

Anonymous reader poll. Unscientific, not investment advice.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Founded: 2006
CEO: Dr. Dinesh V. Patel, PhD
Employees: 132
Headquarters: Newark, California, United States of America
Fiscal year end: 12-31
Website: protagonist-inc.com

Company profile

Exchange: US
Symbol: PTGX
Market-cap rank: #1570
Listing date: 2016-08-11
Market cap: 9.12B
Float cap: 7.45B
Shares out: 64.71M
Float shares: 52.89M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 04:39:03 · For reference only, not investment advice and not tailored to your situation.